2025 Regular SessionMaryland Legislature

HB1109: Public Health - Medetomidine and Xylazine Consumer Protection Act

Legislative Summary

Prohibiting a retailer from distributing, selling, or exposing for sale a medetomidine product or a xylazine product unless the purchaser provides to the retailer certain proof; prohibiting a retailer from distributing, selling, or exposing for sale a medetomidine product or a xylazine product to an individual under the age of 21 years; requiring a retailer that prepares, distributes, sells, or exposes for sale a medetomidine product or a xylazine product to maintain certain records; etc.

Demographic Impact

Overall analysis of equity impact

Neutral
High ConfidenceView detailed demographic breakdown ↓

Unlock Full Demographic Insights

Go beyond the overall score.

Gain a deeper understanding of this bill's potential impact across diverse communities, including detailed breakdowns by category and subgroup. Access to this granular analysis helps ensure equitable outcomes.

Enable full analysis features for your organization.

Contact Sales to Learn More

Or email us directly at sales@legiequity.us.

Bill History

2/5/2025
First Reading Health and Government Operations
House of Delegates
2/10/2025
Hearing 3/05 at 1:00 p.m.
House of Delegates
3/3/2025
Hearing canceled
House of Delegates
3/3/2025
Hearing 3/05 at 2:00 p.m.
House of Delegates
3/5/2025
Hearing canceled
House of Delegates
3/5/2025
Hearing 3/05 at 2:40 p.m.
House of Delegates

Status Information

Current Status
Introduced(2/5/2025)
Chamber
House of Delegates
Committee
Health and Government Operations(House of Delegates)

Sponsors

Republican: 1

Primary Sponsor

Jesse Pippy
Jesse Pippy
Republican

Documents

Introduced
Bill Text2/5/202599.9 KB